190 related articles for article (PubMed ID: 24392996)
1. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus.
Pfützner A; Hermanns N; Funke K; Forst T; Behnke T; Bitton G; Nagar R; Raz I; Haak T
Curr Med Res Opin; 2014 May; 30(5):753-60. PubMed ID: 24392996
[TBL] [Abstract][Full Text] [Related]
2. Standardized modulation of the injection site allows for insulin dose reduction without deterioration of metabolic control.
Pfützner A; Dissel S; Forkel C; Grenningloh M; Bitton G; Nagar R; Forst T
Curr Med Res Opin; 2014 Oct; 30(10):2001-8. PubMed ID: 24940825
[TBL] [Abstract][Full Text] [Related]
3. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
4. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
5. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia rates with basal insulin analogs.
Little S; Shaw J; Home P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
[TBL] [Abstract][Full Text] [Related]
7. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
Vora J; Heise T
Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
9. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP
Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
[TBL] [Abstract][Full Text] [Related]
11. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
13. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus.
Alemzadeh R; Berhe T; Wyatt DT
Pediatrics; 2005 May; 115(5):1320-4. PubMed ID: 15867042
[TBL] [Abstract][Full Text] [Related]
14. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia.
Hsia E; Seggelke S; Gibbs J; Hawkins RM; Cohlmia E; Rasouli N; Wang C; Kam I; Draznin B
J Clin Endocrinol Metab; 2012 Sep; 97(9):3132-7. PubMed ID: 22685233
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL
Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro).
Rabasa-Lhoret R; Bourque J; Ducros F; Chiasson JL
Diabetes Care; 2001 Apr; 24(4):625-30. PubMed ID: 11315820
[TBL] [Abstract][Full Text] [Related]
18. A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
Manner DH; Luo J; Qu Y; Berry S; Gaydos BL; Jacober SJ
Diabetes Technol Ther; 2014 Aug; 16(8):499-505. PubMed ID: 24825416
[TBL] [Abstract][Full Text] [Related]
19. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
[TBL] [Abstract][Full Text] [Related]
20. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M
Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
